Stockholm March 24, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Nomination Committee for BioArctic AB provides the following proposals for resolution at the annual general meeting on May 7, 2020 regarding the number of board members and the election of board members.
The Nomination Committee proposes that the board shall consist of eight members, without deputies.
The Nomination Committee proposes that Wenche Rolfsen, Ivar Verner, Lars Lannfelt, Pär Gellerfors, Hans Ekelund, Eugen Steiner and Mikael Smedeby be re-elected as board members and that Håkan Englund be elected as new board member, each for a term of office until the end of the next annual general meeting. Further, the Nomination Committee proposes that Wenche Rolfsen be re-elected as chairperson of the board and that Ivar Verner be re-elected as deputy chairperson of the board.
The board member Ewa Björling has informed the Nomination Committee that she will not be standing for re-election.
Håkan Englund has training in chemistry and economics from KTH and Uppsala University, respectively, and has more than 40 years of experience in the life science industry. Håkan Englund has held several leading commercial roles in sales and marketing within the Pharmacia group and is expected to contribute to the board with valuable expertise in these areas. Håkan Englund also has experience from several board assignments in both public and private companies in the life science sector. Håkan Englund is independent in relation to the company, the company’s management and its major shareholders.
Information on all proposed board members in BioArctic, the Nomination Committee’s reasoned opinion regarding the proposal for the election of board members and the Nomination Committee’s complete proposals to the annual general meeting will be available on the company’s website, www.bioarctic.com, in connection with the issuance of the notice to attend the annual general meeting 2020, which is expected to be published around April 8, 2020.
The Nomination Committee has been appointed according to the principles adopted by the annual general meeting 2019 and consists of Gunnar Blix (chairperson), appointed by the Third Swedish National Pension Fund (sw: Tredje AP-fonden), Margareta Öhrvall, appointed by Demban AB and Claes Andersson, appointed by Ackelsta AB. The composition of the Nomination Committee was published on November 5, 2019 and has been made available on the company’s website. The members of the Nomination Committee have been appointed by shareholders who together represent approximately 64 percent of the shares and approximately 85 percent of the votes in the company. The chairperson of the board has been adjunct at the meetings of the Nomination Committee.
The Nomination Committee of BioArctic AB (publ)
For further information, please contact:
Gunnar Blix, Chairperson of the Nomination Committee, telephone + 46 (0) 8 555 17 173
Wenche Rolfsen, Chairperson of the Board of Directors, telephone +46 (0)73 331 91 56
This information was submitted for publication at 08:00 a.m. CET on March 24, 2020.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.